Related Experiment Video
Updated: Apr 11, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
25.2K
IDH Mutation Analysis in Ewing Sarcoma Family Tumors
Ki Yong Na1, Byeong-Joo Noh2, Ji-Youn Sung3
1Department of Pathology, Central Physical Examination Agency, Daegu, Korea.
Journal of Pathology and Translational Medicine
|May 29, 2015
Summary
Isocitrate dehydrogenase (IDH) mutations are rare in Ewing sarcoma family tumors (ESFTs). This study found four ESFT cases with IDH mutations, suggesting they can occur in known hot-spot regions.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Isocitrate dehydrogenase (IDH) is crucial for cellular metabolism, producing alpha-ketoglutarate (α-KG) and NADH.
- IDH dysfunction leads to oncometabolite accumulation (2-hydroxyglutarate), oxidative damage, and hypoxia, promoting tumorigenesis.
Purpose of the Study:
- To investigate the presence and characteristics of IDH mutations in Ewing sarcoma family tumors (ESFTs).
Main Methods:
- Analysis of IDH mutations in 61 ESFTs using pentose nucleic acid clamping and direct sequencing.
Main Results:
- Four cases (rare incidence) of ESFTs with IDH mutations were identified.
- IDH1 and IDH2 mutations occurred with equal frequency and showed variable subtypes.
- No significant clinicopathologic differences were observed based on IDH mutation status.
Conclusions:
- This is the first report of IDH mutations in ESFTs.
- ESFTs can harbor IDH mutations in known hot-spot regions, though rarely.
- Larger studies are needed to confirm prevalence and biological significance.
